Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The American College of Surgeons Oncology Group Z1071 trial in 2013 demonstrated the fesability of sentinel lymph node biopsy in clinically node-positive patients following neoadjuvant chemotherapy. The goal of this study was to determine the continued impact of this study on our practice pattern.
Materials And Methods: This is a retrospective review of institutional changes in the management of axillary nodal disease following the publication of Z1071. Patients with clinically node-positive disease that completed neoadjuvant chemotherapy between 2014 and 2020 were included. The Cocoran-Armitage trend test was used to analyze change in categorical variables over time, and the Spearman's rank coefficient was used to analyze two-ranked variables.
Results: A cohort of 102 patients were included in the study and demonstrated that the number of sentinel lymph node biopsies to evaluate axillary disease increased over time. Additionally, the number of biopsies of suspicious nodes, and the use of marker clips on the biopsied nodes increased over time.
Conclusion: Our institution has continued to incorporate the result from Z1071 in our practice patterns.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/00031348211050803 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASO Visual Abstract: Additional Axillary Disease After Neoadjuvant Chemotherapy in patients with Clinically Node-Negative but Sentinel Node-Positive disease.
Ann Surg Oncol
September 2025
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Diagnostic yield of routine frozen section pathology examination of lymph nodes in lung resections for clinical stage IA NSCLC.
J Thorac Cardiovasc Surg
August 2025
Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN. Electronic address:
Objective: Intraoperative identification of lymph node involvement by carcinoma has an impact on the surgical treatment of patients with clinical stage IA NSCLC. This study aimed to identify the diagnostic performance of routine intraoperative frozen section pathology (FSP) evaluation of lymph nodes in these patients.
Methods: Patients with clinical stage IA NSCLC who underwent curative-intent lung resections during 2018-2023 were included.
Treatment Patterns and Outcomes in Lymph-Node-Positive (pN1) Prostate Cancer: A National Cancer Database Study.
Clin Genitourin Cancer
August 2025
Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:
Introduction: Lymph node involvement after radical prostatectomy (pN1) is associated with worse oncologic outcomes, yet its optimal management remains controversial. We evaluated oncologic outcomes and treatment patterns in pN1 prostate cancer.
Patients And Methods: We analyzed data from the National Cancer Database (NCDB) on men undergoing radical pN1 between 2010 and 2020.
MUlticentre REtrospective comparison of definitive EBRT with or without HDR BRAchytherapy boost in patients with locally-advanced prostate cancer and regional lymph NOde metastases (MUREBRANO) - A propensity score matched analysis.
Radiother Oncol
August 2025
Brachytherapy Department, Greater Poland Cancer Centre, Poznań, Poland; Electroradiology Department, University of Medical Sciences, Poznań, Poland. Electronic address:
Background: Patients treated for clinically node-positive prostate cancer (PCa) are at high risk of recurrence. Local radiation dose escalation with brachytherapy (BT) has been shown to improve outcomes in advanced localised disease, but evidence is lacking for patients with pelvic lymph node metastases.
Methods: We retrospectively collected data on patients treated for clinically node-positive PCa with definitive external beam radiation therapy (EBRT) and androgen-deprivation therapy (ADT), with or without dose-escalation to the prostate using high-dose-rate (HDR)-BT.
Iodine Seed-Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer.
JAMA Oncol
August 2025
Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Importance: Most patients with clinically node-positive (cN+) breast cancer receive primary systemic treatment (PST) followed by axillary lymph node dissection (ALND) and/or locoregional radiation (RT). The necessity of axillary treatment in patients achieving nodal pathologic complete response (pCR) after PST remains uncertain.
Objective: To assess oncologic outcomes of response-guided axillary treatment determined by marking the axillary lymph node with a radioactive iodine seed (MARI) in patients with cN+ breast cancer who experience pCR after PST.